DeCure for Pontocerebellar hypoplasia, hypotonia, and respiratory insufficiency syndrome, neonatal lethal
DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for pontocerebellar hypoplasia, hypotonia, and respiratory insufficiency syndrome, neonatal lethal — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePontocerebellar hypoplasia, hypotonia, and respiratory insufficiency syndrome, neonatal lethal maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pontocerebellar hypoplasia, hypotonia, and respiratory insufficiency syndrome, neonatal lethal is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Pontocerebellar hypoplasia type 6 (PCH6) is caused by mutations in the RARS2 gene, which encodes mitochondrial arginine-transfer RNA synthetase. In a 2010 case of a female infant born to nonconsanguineous British parents, the neonatal presentation included increased respiratory rate, poor feeding, and transiently elevated blood and CSF lactate. She later showed profound developmental delay and severe microcephaly. Cranial MRI at 14 months showed generalised cerebral atrophy, thinning of the pons, and gross atrophy and flattening of the cerebellar hemispheres. Muscle biopsies on two occasions were normal, with normal respiratory chain studies. Two novel pathogenic RARS2 mutations were identified. The authors note that respiratory chain abnormalities are not obligatory in PCH6, and that some features of PEHO (progressive encephalopathy, oedema, hypsarrhythmia, optic atrophy) may be present — in this case oedema of the hands, feet, and face was seen, but optic atrophy and hypsarrhythmia were absent.
A 1999 report describes a girl born at 33 weeks gestation with respiratory insufficiency and multiple contractures. MRI showed pontocerebellar hypoplasia and cortical and diffuse periventricular white matter abnormalities. Postmortem examination found pontocerebellar hypoplasia with extensive gliosis of the periventricular white matter and basal ganglia, but normal spinal cord findings. Histology of skeletal muscle was normal. Biochemical analysis demonstrated multiple deficiencies of respiratory chain enzymes in skin fibroblasts. The authors conclude that a lethal phenotype of pontocerebellar hypoplasia without spinal cord abnormalities can be associated with a respiratory-chain disorder, and that diagnostic workup should include a search for respiratory-chain impairment.
A 2010 autopsy case describes a child with later-onset pontocerebellar hypoplasia type 1, with symptoms beginning at 20 months and death at 15 years. Pathological findings showed anterior horn cell degeneration and pyramidal tract involvement in addition to pontocerebellar atrophy. The authors state that the degenerative pattern in this later-onset case was similar to that of prenatal-onset cases. They note that further reports with histopathological examination are needed to clarify the nosology and aetiology of the disorder.
No drug treatment is mentioned in any of these abstracts. What is missing for any potential therapeutic approach is a clear molecular target, any preclinical model system for drug screening, and any clinical trial design — including patient stratification by genetic subtype or by the presence or absence of respiratory chain defects. Funding for natural history studies and for the development of outcome measures in this neonatal lethal population is absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2010 · 71 citations
Pontocerebellar hypoplasia type 6: A British case with PEHO‐like features
AbstractSix subtypes of autosomal recessive pontocerebellar hypoplasia (PCH) have been identified and the genetic basis of four of these (PCH1, PCH2, PCH4, and PCH6) is known. PCH6 is associated with cerebral atrophy and multiple but variable respiratory chain defects in muscle and has been reported in one consanguineous Sephardic Jewish family. It is caused by mutations in the RARS2 gene which encodes mitochondrial arginine-transfer RNA synthetase. Here we describe a female patient born to nonconsanguineous British parents. She presented in the neonatal period with increased respiratory rate, poor feeding and transiently elevated blood and CSF lactate levels. She went on to manifest profound developmental delay and severe microcephaly. Edema of the hands, feet, and face were suggestive of a PEHO-like condition (progressive encephalopathy, edema, hypsarrhythmia and optic atrophy), although optic atrophy and hypsarrhythmia were absent. Cranial MRI at age 14 months showed generalized cerebral atrophy, thinning of the pons and gross atrophy and flattening of the cerebellar hemispheres. Muscle biopsies on two occasions were normal with normal respiratory chain studies. Despite the absence of respiratory chain defects, the phenotype was felt to be consistent with PCH6 and indeed two novel pathogenic RARS2 mutations were identified. Ours is the second report of PCH6 due to RARS2 mutations and demonstrates that respiratory chain abnormalities are not obligatory, whereas some features of PEHO might be present.
Pontocerebellar Hypoplasia Associated with Respiratory-Chain Defects
AbstractPontocerebellar hypoplasias are congenital disorders of brain morphogenesis which include such diverse etiologies as carbohydrate-deficient glycoprotein syndrome type 1, cerebromuscular dystrophies (Walker-Warburg syndrome, Fukuyama syndrome, muscle-eye-brain disease) and at least two types of autosomal recessive neurodegenerations known as pontocerebellar hypoplasia type I and II. Pontocerebellar hypoplasia type 1 is a lethal phenotype and clinical features include congenital contractures, respiratory insufficiency, central and peripheral motor dysfunction and spinal anterior horn degeneration. Type 2 is characterized by progressive microcephaly, extrapyramidal dyskinesia and normal spinal cord findings. In this paper, we describe a girl, born at 33 weeks of gestation, presenting with respiratory insufficiency and multiple contractures. MRI scan of the brain demonstrated pontocerebellar hypoplasia and cortical and diffuse periventricular white matter abnormalities. Postmortem examination showed pontocerebellar hypoplasia with extensive gliosis of the periventricular white matter and of the basal ganglia with normal spinal cord findings. Histology of skeletal muscle was normal. Biochemical analysis demonstrated multiple deficiencies of respiratory chain enzymes in skin fibroblasts. This case demonstrates a lethal phenotype of pontocerebellar hypoplasia without spinal cord abnormalities associated with a respiratory-chain disorder. The diagnostic workup in a patient whose brain image shows pontocerebellar hypoplasia should include a search for respiratory-chain impairment.
Journal of Child Neurology · 2010 · 3 citations · open access
Autopsy Case of Later-Onset Pontocerebellar Hypoplasia Type 1: Pontine Atrophy and Pyramidal Tract Involvement
AbstractThe combination of pontocerebellar hypoplasia and anterior horn cell degeneration is classified as pontocerebellar hypoplasia type 1. Although most cases exhibit severe muscle weakness and hypotonia neonatally with short life spans, some cases exhibit a later onset with a longer life span and show cerebellar atrophy without pontine involvement. We present a child who exhibited neurological deterioration and progressive atrophy of the cerebellum and pons, with onset of symptoms at 20 months and death at 15 years of age. The pathological findings disclosed anterior horn cell degeneration and pyramidal tract involvement in addition to pontocerebellar atrophy, leading to the diagnosis of pontocerebellar hypoplasia type 1. The present case suggests that the degenerative pattern of later-onset pontocerebellar hypoplasia type 1 is similar to that of prenatal-onset cases. Further reports of later-onset cases with histopathological examination are required to elucidate the nosology and etiology of the disorder.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
